5 minutes to Read

The antihypertensive medicine Accuretic (quinapril in combination with hydrochlorothiazide), is being withdrawn. Prescribers are advised to change all patients taking Accuretic to alternative medicine(s) when their next monthly prescription is due. Read our article for dose equivalence tables and information on switching, monitoring, co-payments and consultation fees.
 

Contributor
Dr Noni Richards
4 July 2022
1 minute to Read

Although triple therapy can reduce the risk of recurrent CVD events by at least 50 per cent over five years, the He Ako Hiringa EPiC dashboard indicates only half of people receive all three types of medicines following a CVD event. Read our latest bulletin for more on triple therapy and team-based initiatives that may help identify and prioritise patients for intensive management.

Contributor
He Ako Hiringa
1 July 2022
60 minutes to Delve

Explore your prescribing further with EPiC Reflect CVD. This activity helps you to delve into your EPiC data, contemplate your prescribing, reflect on your current practice, and set goals and actions. Available as an editable PDF document, EPiC Reflect helps you to incorporate your learning into your everyday practice.

Contributor
He Ako Hiringa
9 June 2022
1 minute to Read

The current primary care CVD management guidance strongly recommends aggressive risk management and lifestyle modification in patients with pre-existing CVD or an equivalent CVD risk. Significant opportunities to improve use of CVD medicines remain, particularly for Māori and Pacific peoples who lose 2.6–2.8 times more years to CVD events relative to non-Māori/non-Pacific peoples.

Contributor
He Ako Hiringa
30 March 2022
1 minute to Read

Cardiovascular disease is the leading cause of death in New Zealand, accounting for 35 per cent of mortality in 2019. Yet it’s preventable and treatable. Māori, Pacific, and South Asian peoples have a disproportionately higher CVD risk compared with people not of these ethnicities. Therefore, CVD risk assessments in these ethnicities should begin earlier.

Contributor
He Ako Hiringa
28 January 2022
10 minutes to Read + 2 minutes to Watch

Rosuvastatin is now fully funded on Special Authority for people at increased risk of cardiovascular complications due to high cholesterol, and may be considered first-line for Māori and Pacific peoples.

An abridged version of this article, containing the eligibility flowchart, is available for printing - see the link in the contents box. 

Contributor
He Ako Hiringa
15 November 2021
60 minutes to Watch

In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.

Contributor
Dr Raewyn Fisher
24 August 2021